Real‐world effectiveness and safety of RC48‐ADC alone or in combination with PD‐1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study

Abstract Introduction Previous RC48 (Disitamab Vedotin) studies established that the safety and efficacy of RC48‐antibody–drug conjugate (ADC), either alone or combined with toripalimab, for metastatic urothelial carcinoma (mUC) patients exhibiting human epidermal growth factor receptor 2 (HER2)‐pos...

Полное описание

Библиографические подробности

Главные авторы:	Jingwei Xu, Hongqiao Zhang, Li Zhang, Xiufeng Chu, Yu Li, Guangyuan Li, Caiyun Nie, Meng Wang, Yanwei Guo
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2023-12-01
Серии:	Cancer Medicine
Предметы:	antibody–drug conjugate disitamab vedotin metastatic urothelial carcinoma real‐world study
Online-ссылка:	https://doi.org/10.1002/cam4.6680
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!